COMMUNIQUÉS West-GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/01/2025
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity [...]
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
07/01/2025
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, [...]
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
07/01/2025
Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety results Completed dosing in the first two Multiple Ascending [...]
Glucotrack to Present at TechBio Showcase™ 2025
07/01/2025
Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes RUTHERFORD, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or [...]
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
07/01/2025
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
07/01/2025
NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for [...]
OraSure to Present at the J.P Morgan Healthcare Conference
07/01/2025
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its [...]
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
07/01/2025
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered [...]
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
07/01/2025
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma
07/01/2025
The study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates [...]
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07/01/2025
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive [...]
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07/01/2025
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, [...]
Ipsen - Half year statement - 2024 12 31
07/01/2025
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF Boulogne-Billancourt (France), January 7 th , 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, [...]
Ipsen - Bilan semestriel - 31 12 2024
07/01/2025
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF Boulogne-Billancourt (France), le 7 janvier 2025 - Au titre du contrat de liquidité confié par IPSEN SA à NATIXIS ODDO BHF, à la date du 31 [...]
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/01/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Décembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/01/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
SAFE GROUP - 16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires: presentation of Professor Maestretti's clinical results on the Sycamore device
07/01/2025
16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires: presentation of Professor Maestretti's clinical results on the Sycamore device Fleurieux-sur-l'Arbresle - France – January 7, 2025 at [...]
SAFE GROUP - 16èmes Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires : présentation des résultats cliniques du Professeur Maestretti sur le dispositif Sycamore
07/01/2025
16èmes Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires : présentation des résultats cliniques du Professeur Maestretti sur le dispositif Sycamore Fleurieux-sur-l’Arbresle - France - le 7 [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
07/01/2025
Déclaration de transactions sur actions propres Paris, France (7 janvier 2025, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2024, EssilorLuxottica déclare que du 2 janvier 2025 au [...]

Pages